Product Revenues, Accounts Receivable, and Reserves for Product Sales	6 Months Ended
Jun. 30, 2022
Product Revenues Accounts Receivable And Reserves For Product Sales [Abstract]
Product Revenues, Accounts Receivable, and Reserves for Product Sales	3. Product Revenues, Accounts Receivable, and Reserves for Product Sales The Company received FDA approval for the sale of EMPAVELI in the United States in May 2021. The Company’s product revenues, net of sales discounts and allowances and reserves, for the three months ended June 30, 2022 and 2021 were $15.7 million and $0.6 million, respectively. The Company’s product revenues, net of sales discounts and allowances and reserves, for the six months ended June 30, 2022 and 2021 were $27.8 million and $0.6 million, respectively. The Company’s accounts receivable balance of $7.5 million as of June 30, 2022 and $10.1 million as of December 31, 2021, consisted of EMPAVELI product sales receivable, net of discounts and allowances of $0.3 million and $0.2 million, respectively. The Company does not have a reserve against its receivable balance. The Company’s product sales reserves totaled $2.5 million and $1.0 million as of June 30, 2022 and December 31, 2021, respectively. These amounts are included in accrued expenses on the Company’s unaudited condensed consolidated balance sheet.

Product Revenues, Accounts Receivable, and Reserves for Product Sales

6 Months Ended

Jun. 30, 2022

Product Revenues Accounts Receivable And Reserves For Product Sales [Abstract]

Product Revenues, Accounts Receivable, and Reserves for Product Sales

3. Product Revenues, Accounts Receivable, and Reserves for Product Sales

The Company received FDA approval for the sale of EMPAVELI in the United States in May 2021. The Company’s product revenues, net of sales discounts and allowances and reserves, for the three months ended June 30, 2022 and 2021 were $15.7 million and $0.6 million, respectively. The Company’s product revenues, net of sales discounts and allowances and reserves, for the six months ended June 30, 2022 and 2021 were $27.8 million and $0.6 million, respectively.

The Company’s accounts receivable balance of $7.5 million as of June 30, 2022 and $10.1 million as of December 31, 2021, consisted of EMPAVELI product sales receivable, net of discounts and allowances of $0.3 million and $0.2 million, respectively. The Company does not have a reserve against its receivable balance.

The Company’s product sales reserves totaled $2.5 million and $1.0 million as of June 30, 2022 and December 31, 2021, respectively. These amounts are included in accrued expenses on the Company’s unaudited condensed consolidated balance sheet.